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ABSTRACT 25	  
Introduction Bacterial bloodstream infection (BSI) is a common cause of morbidity and 26	  
mortality in sub-Saharan Africa yet few facilities are able to conduct long-term surveillance. The 27	  
Malawi-Liverpool-Wellcome Trust Clinical Research Programme has conducted sentinel 28	  
surveillance of bacteraemia since 1998. We report long-term trends in BSI and antimicrobial 29	  
resistance (AMR) from this surveillance.  30	  
Methods Blood cultures were routinely taken from adult and paediatric medical patients 31	  
admitted to QECH with fever or suspicion of sepsis since 1998. Antimicrobial susceptibility tests 32	  
were performed by the disc diffusion method according to BSAC guidelines. We analysed these 33	  
data to describe trends in BSI and AMR from 1998-2016. 34	  
Findings 29,183 pathogens were isolated from 194,539 blood cultures. There was a significant 35	  
decline in pathogen detection from 327·1/100,000/year to 120·2/100,000/year in 2016 36	  
(p<0·0001). 13,366/26,174 (51·1%) bacterial isolates were resistant to the Malawian first-line 37	  
agents amoxicillin/penicillin, chloramphenicol and cotrimoxazole; 68·3% amongst Gram-38	  
negative and 6·6% of Gram-positive pathogens. The proportions of non-Salmonellae 39	  
Enterobacteriaceae with ESBL or fluoroquinolone resistance rose significantly after 2003 to 40	  
61·9% in 2016 (p<0·0001). In contrast, over 92·0% of common Gram-positive pathogens remain 41	  
susceptible to either penicillin or chloramphenicol. Methicillin resistant S. aureus (MRSA) was 42	  
first reported in 1998 and represented 18·4% of S. aureus isolates in 2016. 43	  
Interpretation The rapid expansion of ESBL and fluoroquinolone resistance amongst common 44	  
Gram-negative pathogens and emergence of MRSA highlight the growing challenge of BSIs that 45	  
are effectively impossible to treat in this resource-limited setting.  46	  
Funding Wellcome Trust, H3ABionet and Southern Africa Consortium for Research Excellence 47	  
(SACORE). 48	  
 49	  
  50	  
 51	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INTRODUCTION 52	  
Bloodstream infection (BSI) is a leading cause of morbidity and mortality in both adults and 53	  
children in sub-Saharan Africa (SSA).1 In this region, the high burden of bacterial BSI has been 54	  
strongly associated with the high prevalence of human immunodeficiency virus (HIV), malaria 55	  
and malnutrition.1-4 The clinical impact of BSI in SSA is exacerbated by inadequacy of 56	  
diagnostic facilities, precluding both timely diagnosis of severe bacterial infection and 57	  
implementation of appropriate antimicrobial therapy.5 58	  
Sentinel bacteraemia surveillance has been conducted at Queen Elizabeth Central Hospital 59	  
(QECH), Blantyre, Malawi, a setting with high prevalence of HIV, malaria and malnutrition 60	  
since 19986 and  Nontyphoidal Salmonellae (NTS), S. Typhi and Streptococcus pneumoniae 61	  
were previously identified as leading causes of BSI.6-8 Widespread multidrug resistant (MDR) 62	  
NTS necessitated the introduction and increasingly extensive use of ciprofloxacin (2002) and 63	  
ceftriaxone (2004) for the empirical management of sepsis.7,9 Extended spectrum beta-lactamase 64	  
(ESBL) producing and fluoroquinolone resistant (FQR) Enterobacteriaceae have been reported in 65	  
different settings around the globe where cephalosporins and fluoroquinolones have been in 66	  
use.10-14 This includes Blantyre, where ESBL-producing and FQR E. coli, Klebsiella and 67	  
Salmonellae isolates were previously identified,15-17 however, the full burden of ESBL and FQR 68	  
among the Gram-negative pathogens in this setting has yet to be described.  69	  
In contrast, among Gram-positive pathogens we have previously reported fluctuating levels of 70	  
pneumococcal resistance to penicillin ranging from 9·0-18·0%,8 as has also been reported in 71	  
other African settings.18 Few studies in SSA have described the prevalence of methicillin 72	  
resistant Staphylococcus aureus (MRSA) and although in Malawi the geographical ubiquity of 73	  
MRSA has increased, its prevalence remains unknown.19 74	  
Both long-term bacteraemia and AMR surveillance data are scarce in SSA. Here, we have used 75	  
our comprehensive sentinel surveillance dataset to describe longitudinal trends in BSI and AMR 76	  
over a 19-year period at a large teaching hospital in Blantyre, Malawi, with particular focus on  77	  
prevalence of ESBL and FQR among Gram-negative pathogens and the emergence of MRSA. 78	  
 79	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METHODS 80	  
Study Setting 81	  
Blantyre is one of two principal cities in Malawi and during the study period, both its urban and 82	  
peri-urban rural areas, had a rapidly expanding population, which was estimated at 1.3 million in 83	  
2016. There is a high burden of HIV, malaria and malnutrition, however during the study period 84	  
antiretroviral therapy (ART) programmes, malaria control interventions and improvements in 85	  
food security and community management of malnutrition were rolled out. HIV prevalence in 86	  
Blantyre has declined from 22.3% in 2004 to 17·6% in 2016, whilst enrolment on the ART 87	  
programme in Malawi has increased from 4,000 (2·3% of those in need of ART) in 2004 to over 88	  
530,000 (67·0% those in need of ART) in 2014. 20-23 Conjugate vaccine introductions against 89	  
Haemophilus influenza type b (2002) and pneumococcus (2011) occured.24-26 Over the period of 90	  
BSI surveillance, there were also considerable reductions in mortality among children less than 91	  
five years of age and among  HIV-infected adults.16,27,28 92	  
QECH is one of the largest government hospitals in Malawi and is the only public hospital 93	  
providing free medical care to  Blantyre city, serving an urban population estimated at 920,000 94	  
in 2016. There are approximately 1,000 physical beds, though occupancy frequently exceeds 95	  
capacity. The hospital admits approximately 10,000 adult (aged≥16 years) and 30,000 paediatric 96	  
(aged< 16 years) medical patients/year. From 1998-2015,  empirical management of sepsis was 97	  
either with chloramphenicol and benzylpenicillin, or ceftriaxone, which was introduced in 98	  
Malawi in 2004. Ceftriaxone was not widely available in the city or district of Blantyre outside 99	  
of QECH, however it was extensively used as a first-line agent at QECH and was empirically 100	  
given to 90·0% of febrile adult patients admitted to QECH in one study in 2009/10.16  101	  
Diagnostic microbiology procedures 102	  
The Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) has provided 103	  
routine, quality controlled, diagnostic blood culture (BC) service for febrile adult and paediatric 104	  
medical patients admitted to QECH since 1998. A recommended seven to ten mls of blood were 105	  
taken for culture under aseptic conditions from all adult patients admitted to the hospital with 106	  
fever (axillary temperature > 37.5°C) or clinical suspicion of sepsis, severe sepsis or septic 107	  
shock.29 Clinicians were able to asses the following features of the systemic inflammatory 108	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response syndrome and severe sepsis at a patient’s bed-side in order to inform their decision to 109	  
draw blood for culture; tachycardia (≥ 90 beats/minute), hypotension (systolic blood pressure < 110	  
90 mmHg), tachypnoea (respiratory rate > 20/minute) and delirium. The presence of fever and 111	  
one or more of these features would lead the clinician to take a blood culture. A recommended 112	  
three to ten mls of blood were also taken from children with the following criteria; non-focal 113	  
febrile illness who tested negative for malaria, severely ill with suspected sepsis, or patients who 114	  
failed initial malaria treatment and remained febrile.8 In this extremely busy hospital afebrile 115	  
patients were unlikely to have blood sampled for culture unless critically ill with suspected 116	  
sepsis. The blood was inoculated into a single aerobic bottle (BacT/Alert, bioMérieux Marcy-117	  
L'Etoile, France).6   118	  
BC was undertaken using the automated BacT/ALERT system (bioMérieux, France) since 2000, 119	  
prior to which manual culture was used and the method has previously been described.30 120	  
Enterobacteriaceae and oxidase positive Gram-negative bacilli were identified by API 121	  
(BioMérieux, France), Staphylococci by tube coagulase, ß-haemolytic Streptococci by 122	  
Lancefield antigen testing and Salmonellae by  serotyping according to the White-Kauffmann-Le 123	  
Minor scheme by the following antisera; polyvalent O & H, O4, O9, Hd, Hg, Hi, Hm, and Vi 124	  
antisera (Pro-Lab Diagnostics, UK). The identification of a sample of isolates identified as 125	  
Salmonella enterica serovar Typhimurium was subsequently confirmed by whole genome 126	  
sequencing and multilocus sequence typing. Haemophilus influenza were typed using type B 127	  
antisera. Bacteria that form part of the normal skin or oral flora including: Diphtheroids, Bacilli., 128	  
Micrococci., coagulase negative Staphylococci, and alpha-haemolytic Streptococci (other than S. 129	  
pneumoniae) were considered to be contaminants.31 130	  
Antimicrobial susceptibility tests were performed by the disc diffusion method following the 131	  
British Society of Antimicrobial Chemotherapy (BSAC) methods and breakpoints 132	  
(www.bsac.org.uk). Testing was in most cases limited to one plate containing six discs and the 133	  
choice of agent has varied depending on the range of antimicrobials available to clinicians. The 134	  
most current standard operating  procedures are included in Supplementary Methods. Bacteria 135	  
were defined as being resistant to Malawian first-line agents (hereafter, resistant to first-line or 136	  
RFL) if they were resistant to the three first-line antimicrobial agents commonly used in Malawi, 137	  
namely amoxicillin, cotrimoxazole and chloramphenicol for Gram-negative isolates, or 138	  
penicillin, cotrimoxazole, and chloramphenicol for Gram-positive isolates. Isolates were 139	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considered MDR if they were found to be resistant to three or more classes of antimicrobials to 140	  
which reference strains are susceptible.32 Gram negative isolates have been screened for ESBL-141	  
producing status using a cefpodoxime disc since 2007. Prior to this, ESBL was inferred based on 142	  
resistance to ceftriaxone. ESBL was not confirmed. Methicillin resistance in S. aureus was 143	  
inferred by cefoxitin resistance, which replaced oxacillin resistance testing in 2010. 144	  
Statistics 145	  
We have reported prevalence of BC collection at MLW and causes of BSI in Blantyre using 146	  
frequency distributions. Minimum annual incidence rates were expressed as incidence per 147	  
100,000 age-specific person years and estimated by dividing the number of BSI cases by mid-148	  
year population and multiplying by 100,000.  We used the Cochran-Armitage test for trend and 149	  
negative binomial regression to examine association between BSI incidence and time. Age 150	  
stratified population estimates for urban Blantyre for the years 1998-2007 were obtained from 151	  
the 1998 National Population Projections and for the years 2008-2016 from the 2008 National 152	  
Population Projections by the National Statistical Office  (NSO; http://www.nsomalawi.mw). 153	  
Statistical analyses were performed using R Statistical Package version 3.1.2 for MacOS (R Core 154	  
Team, www.r-project.org). 155	  
ETHICS STATEMENT  156	  
MLW BC surveillance at QECH was approved by the College of Medicine Research Ethics 157	  
Committee (COMREC) of the University of Malawi, approval number P.08/14/1614.  158	  
ROLE OF FUNDING SOURCE 159	  
The sponsors of the study had no role in study design, data collection, data analysis, data 160	  
interpretation, or writing of the report. The corresponding author had full access to all the data in 161	  
the study and had final responsibility for the decision to submit the paper for publication. 162	  
RESULTS  163	  
In total, 194,539 blood cultures were collected from January 1998 to December 2016 from adult 164	  
(79,095 [40·7%]) and paediatric (115,444 [59·3%]) patients presenting to QECH. The absolute 165	  
number of BCs collected per year fluctuated during the surveillance, but we observed a declining 166	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trend in ratio of BCs to population size, especially after 2005 (Figure 1A; p<0·0001). 29,183 167	  
(15·0%) BCs yielded pathogens (Table 1), a further 36,763 (18·9%) yielded contaminants 168	  
(Figure 1A & Supplementary Figure 1) and there was no growth from 128,593 (66·1%) BCs 169	  
(Figure 1A).  Estimated incidence rate of BSI also declined substantially during the study period 170	  
(Figure 1A; p<0·0001). The pathogen profiles in children and adults are shown in Supplementary 171	  
Tables 1 & 2 respectively. 172	  
Enterobacteriaceae 173	  
Trends in Salmonella BSI revealing epidemics of NTS which peaked in 2002, and a more recent 174	  
epidemic of Typhoid fever  were previously described in detail up to 20146, but are included in 175	  
Table 1 and Figure 1 to place other causes of BSI in context. Our analysis further shows that the 176	  
S. Typhi epidemic, which had peaked in 2013, has been declining since 2013 (Figure 1B). A total 177	  
of 2,560 E. coli isolates (8·8% BSI cases), 1,281 Klebsiella spp. isolates (4·4% BSI) and 1,130 178	  
isolates of other species from the Enterobacteriaceae family (3·9% BSI) were recorded between 179	  
1998-2016. The most common organisms in in the group of other Enterobacteriaceae species 180	  
were Enterobacter spp., 517, Serratia spp., 211, Citrobacter spp. 185, Proteus spp., 93, and 181	  
Shigella spp., 40 (Table 1). Incidence of BSI attributable to these pathogens significantly 182	  
declined over time (Figure 1B & C; p<0·0001). 183	  
Other Gram-negative pathogens 184	  
Other Gram-negative causes of BSI included Acinetobacter spp. (543), Haemophilus spp. (434), 185	  
Pseudomonas spp. (442), Neisseria spp. (210), other Anaerobes (30) and Vibrio spp. (12). These 186	  
together were responsible for 1,671 (5·7%) positive blood cultures (Figure 1E). 187	  
 188	  
S. pneumoniae 189	  
Trends in S.  pneumoniae BSI were previously described for the period 2000-2009,8 whereas this 190	  
dataset  spans 1998-2016. In total, there were 4,258 S. pneumoniae isolates (14·6% BSI) during 191	  
the period 1998-2016. We observed a significant downward trend in the annual incidence of BSI 192	  
due to S.  pneumoniae (Figure 1B; p<0·0001).  193	  
 194	  
S. aureus 195	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S. aureus was the second most common Gram-positive cause of BSI with 1,923 (6·6% BSI)  196	  
isolates during the study period.  The isolation frequency of S. aureus fluctuated throughout the 197	  
study period (Figure 1D), but the incidence of S. aureus BSI declined significantly (p<0.0001).  198	  
 199	  
Other Gram-positive pathogens 200	  
There were a total of 1,193 (4·5% BSI)  β-haemolytic Streptococcus spp., including 397 (1·4% 201	  
BSI) isolates of Lancefield Group A and 477 (1·6% BSI) isolates of Group B Streptococcus spp. 202	  
and 320 Enterococcus spp  (1·0% BSI) of which 220 (0·8% BSI) isolates were E. faecalis, 76 203	  
(0·3% BSI) isolates were E. faecium and 42 (0·1% BSI) isolates were other Enterococcus spp. 204	  
Whereas the incidence of β-haemolytic Streptococci declined (p=0·0005) during the 205	  
surveillance, there was no significant  change in Enterococci BSI (p=0·4900).  206	  
 207	  
Yeasts 208	  
Our longitudinal bacteraemia surveillance also led to the isolation of 1003 isolates (3.4% BSI) of 209	  
yeast  (Table 1), including 963 Cryptococcus neoformans and 40 Candida species. After 210	  
consistently increasing between 1998 and 2006, the incidence of yeast BSI has been in decline 211	  
since 2006 (Figure 1D). 212	  
 213	  
Age Distribution 214	  
Of the 29,183 episodes of culture-confirmed BSI, age was known in 23,219 (79·6%) cases. 215	  
13,002 (56·0%) cases with known age were children (<16 years) and 8,621 (44·0%) were adults 216	  
(≥16 years old). 10,059 (77·4%) children were aged below five years. Most bacterial species 217	  
associated with BSI in Blantyre displayed a bimodal age distribution, affecting mostly children 218	  
under 5 years of age and adults aged between 20-45 years (Supplementary Figure 2). The only 219	  
exception was S. Typhi, which was most common in children under 10 years of age.6 220	  
Cryptococcal BSI was most common in adults aged between 20 and 45 years, but uncommon in 221	  
children (Supplementary Figure 2). 222	  
 223	  
When the aggregate data were adjusted by age distribution in the population to produce 224	  
minimum incidence estimates stratified by age, a subtly different picture emerged. It was noted 225	  
that the minimum incidence rates for E. coli BSI were greatest in older age groups ≥ 70 years  226	  
(up to 54·3/100,000/year) followed by children aged below five years (37·5/100,000/year); and 227	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for Klebsiella BSI, incidence rates were highest in children below five years (29·2/100,000/year) 228	  
followed by the elderly aged 75-80 years (24·6/100,000/year). For S. Typhi, incidence rates were 229	  
greatest in children between 5-10 years and for all other bacterial pathogens they were greatest in 230	  
those below 5 years of age (Figure 2).  231	  
 232	  
Trends in Antimicrobial resistance  233	  
27,249/28,180 (96·7%) confirmed bacterial BSI isolates were tested for susceptibility to at least 234	  
one antimicrobial agent and 25,752 (91·4%) BSI isolates were tested for susceptibility to at least 235	  
three antimicrobial agents. 13,343/25,572 (52·2%) isolates tested for susceptibility to at least 236	  
three agents were RFL, 10,316/25,572 (40·3%) were resistant to one or two first-line agents, and 237	  
2,093 isolates (8·2%) were susceptible to all three first-line agents (Figure 3). Overall, 238	  
proportions of RFL isolates followed an upward trend during the surveillance period 239	  
(Supplementary Figure 3A; p<0.0001). RFL was markedly more common among Gram-negative 240	  
isolates (12,902/18,887 [68·3%]) than Gram-positive isolates (441/6,685 [6·6%]). 6,129/6,685 241	  
(91·7%) of all Gram-positive isolates were susceptible to either penicillin or chloramphenicol.  242	  
  243	  
Partial return of chloramphenicol susceptibility in E. coli and Klebsiella spp. 244	  
In contrast to the overall trends in RFL isolates,  the proportion of E. coli that were RFL 245	  
substantially declined during the study period (p<0·0001), primarily due to a decline in 246	  
chloramphenicol resistance (Figure 3A; p<0·0001). Chloramphenicol resistance also declined in 247	  
in Klebsiella spp. (p<0·0001), but increased in Salmonellae (Supplementary Figure 3B) , whilst 248	  
no significant trend was detected in other members of the Enterobacteriaceae family ( Figure 3C; 249	  
p=0·2203). 250	  
 251	  
Emergence of ESBL producing, fluoroquinolone and aminoglycoside resistant isolates 252	  
ESBL production was first detected in E. coli in 2004 and in Klebsiella spp. and other 253	  
Enterobacteriaceae in 2003. Both frequency and incidence of ESBL- producing isolates have 254	  
since increased markedly in all non-Salmonellae Enterobacteriaceae (Figure 4; Supplementary 255	  
Figure 4). In addition to the Enterobacteriaceae, a majority (168/274 [61·3%]) of Acinetobacter 256	  
spp. isolates were ESBL producers and there was also an increasing trend of ESBL 257	  
Acinetobacter spp. isolates (Supplementary Figure 5). Ceftazidime was not widely available, 258	  
therefore Pseudomonas isolates were not routinely tested, however 7/9 Pseudomonas isolates 259	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tested were resistant to ceftazidime.  260	  
 261	  
Ciprofloxacin resistance was first detected in Blantyre in Acinetobacter  isolates (1/43 [2·3%])  262	  
in 2001 and in E. coli (4/22 [2·5%)] and Klebsiella isolates in 2003. As with ESBL resistance, 263	  
we observed an increasing trend in both the proportion and rate of non-Salmonellae 264	  
Enterobacteriaceae with resistance to fluoroquinolones (Figure 4). 105/393 (26·7%) and 55/344 265	  
(12·8%) of all Acinetobacter and Pseudomonas isolates were ciprofloxacin resistant. 266	  
 267	  
During the surveillance, we also detected 462/2536 (18·2%) E. coli, 565/1265 (51·9%) 268	  
Klebsiella spp., and 320/1076 (29·7%) of the other Enterobacteriaceae resistant to gentamicin 269	  
with substantial increases in proportions of resistant isolates observed over time (Figure 4). In 270	  
other Gram-negative pathogens, 210/524 (40·1%) Acinetobacter and 140/417(33·6%) 271	  
Pseudomonas isolates were also resistant to gentamicin. 272	  
 273	  
Antimicrobial resistance in Gram-positive pathogens 274	  
 275	  
S. pneumoniae 276	  
Only 37/3,049 (0·9%) S. pneumoniae isolates were resistant to all Malawian first-line agents 277	  
(Figure 3D). Resistance to cotrimoxazole was highly prevalent (3,780/4,087 isolates [92·5%]). In 278	  
contrast, only 610/4,043 (15·1%) isolates were resistant or intermediate resistant to penicillin 279	  
(falling to 551 [13·6%] when intermediate resistance was excluded). The overall trend in 280	  
penicillin resistant isolates was not significant (p=0.2300) but a marked rise was observed 281	  
following the introduction of the pneumococcal conjugate vaccine (PCV13) in 2011 (Figure 3D; 282	  
p<0·0001). 1,074/4,111 (26·1%) isolates were resistant to chloramphenicol. Of isolates tested for 283	  
susceptibility to both chloramphenicol and penicillin, 3,971/4,013 (99·0%) were susceptible to at 284	  
least one of the two antimicrobial agents. We also identified 2,200/4,080 (53·9%) S. pneumoniae 285	  
isolates that were resistant to tetracycline and 92/41,07 (2·2%) S. pneumoniae isolates that were 286	  
resistant to the macrolide erythromycin.  287	  
 288	  
Emergence of MRSA 289	  
In total, 1,151/1,457 (79·0%) S. aureus isolates were resistant to penicillin whilst 828/1895 290	  
(43·7%) were resistant to cotrimoxazole and 452/1898 (23·8%) to chloramphenicol. 107/1,118 291	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(9·6%) S. aureus isolates were MRSA, which was first detected in 1998, but was not regularly 292	  
isolated until 2005 (Figure 3E). Only 20/1,681 S. aureus isolates were tested for susceptibility to 293	  
ciprofloxacin and none was resistant. 206/1,790 (11·5%) isolates tested were resistant to 294	  
gentamicin.  295	  
 296	  
Other Streptococcus and Enterococcus spp. 297	  
855/1,213 (70·5%) of the β-haemolytic Streptococci isolates and 229/325 (70·5%) Enterococci 298	  
isolates were resistant to cotrimoxazole, whereas 176/1149 (15·3%) and 108/176 (61·4%) 299	  
Streptococci and Enterococci spp.  were resistant to penicillin and ampicillin respectively 300	  
208/1143 (17·1%) Streptococci and 198/326 (60·7%) Enterococci were resistant to 301	  
chloramphenicol. Amongst Group A Streptococci, 14/382 (3·7%) were penicillin resistant, 302	  
however these isolates were not speciated and we are therefore unable to specifically identify the 303	  
Streptococcus pyogenes isolates within this group.  304	  
 305	  
Multi-drug resistant and untreatable pathogens 306	  
The majority of Salmonellae, E.coli, Klebsiella, and indeed all other Enterobacteriaceae were 307	  
MDR, as were a substantial proportion of S. pneumoniae, other Streptococci and Enterococci 308	  
Table 2. Trend in MDR isolates was increasing in Klebsiella spp. (p<0·0001) and in other 309	  
Streptococcus spp. and Enterococcus spp. (p<0.0001). We however, detected a declining MDR 310	  
trend ( p<0.0001) in E. coli isolates (Table 2).  311	  
 312	  
381 Gram-negative isolates were resistant to all agents tested against, including amoxicillin, 313	  
cotrimoxazole, chloramphenicol, gentamicin, ciprofloxacin or ceftriaxone, rendering them 314	  
locally untreatable. These included 121/381 (31·8%) Klebsiella spp., 68/381 (17·8%) E. coli, 315	  
119/381 (26·0%) assorted other Enterobacteriaceae and 119/381 (31·2%) Acinetobacter (Figure 316	  
4D).  The number of isolates expressing resistance to all the six agents was 81/1,106 (7·3% BSI) 317	  
in 2016 from 2/2,372 (<0.1%) in 2003 (Figure 4D).  318	  
 319	  
DISCUSSION 320	  
Long term sentinel surveillance in Malawi has revealed a marked decline in the incidence of BSI 321	  
caused by all pathogens between 1998 and 2016. Concurrent with the declining incidence 322	  
however, has been an increase in the prevalence of antimicrobial resistance - including to reserve 323	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antimicrobials.  These changes in the incidence of BSI and the emergence of AMR occurred 324	  
against a background of improvements in food security, malaria control interventions and highly 325	  
successful roll-out of ART. Following the emergence of widespread resistance to commonly 326	  
available first-line antimicrobial agents, cephalosporins and fluoroquinolones have become the 327	  
agents of choice for treatment of severe bacterial infections in SSA including Malawi.33 The 328	  
emergence and spread of ESBL resistance and FQR is therefore a major worry in this setting. 329	  
The rates of ESBL resistance and FQR of up to 30·1% and 31·1% in E. coli and 90·5% and 330	  
70·2% in Klebsiella spp. reported here are very high, whether placed in an African or a global 331	  
context.34-36 Moreover, in the other settings ESBL and  FQR have been reported to be more 332	  
common in hospital acquired than community acquired infections, whereas this study reflects 333	  
community acquired bacteraemia.37,38  334	  
 335	  
Minimum incidence estimates suggest that E. coli and Klebsiella BSI are particularly prominent 336	  
in elderly patients, consistent with global data.39 The Malawi NSO estimates that life expectancy 337	  
in Blantyre will increase from ~55 years in 2007 to ~70 years by 2030 338	  
(http://www.nsomalawi.mw). Increased life expectancy may increase the pool of persons at risk 339	  
of E. coli and Klebsiella BSI, with the attendant risk of drug resistance increasing  the 340	  
prominence of these pathogens with time.  341	  
 342	  
Resistance to first line antimicrobials has fluctuated. In some Enterobacteriaceae such as E. coli 343	  
and Klebsiella spp., RFL rates have begun to decline, primarily due to less chloramphenicol 344	  
resistance. However, the molecular determinants of this observation in E. coli and Klebsiella spp. 345	  
have not been ascertained. This partial re-emergence of chloramphenicol susceptibility is not 346	  
sufficiently great to permit its reintroduction as an agent for the empirical management of sepsis 347	  
in Blantyre, due to widespread resistance amongst Salmonellae, the dominant gram negative 348	  
pathogens.  349	  
 350	  
Chloramphenicol and penicillin have been commonly used in combination for the empirical 351	  
management of sepsis in Malawi for many years.8 It is interesting to note that almost all (99·0%) 352	  
of the S. pneumoniae isolates are still susceptible to this combination despite its wide usage. 353	  
However, it is equally important to note that penicillin resistance has started to increase since the 354	  
introduction of PCV13 in 2011. PCV13 introduction has been associated with a general decline 355	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in penicillin resistant S. pneumoniae in South Africa.40 However, increasing prevalence of 356	  
penicillin resistant S. pneumoniae serotype 19F and non-vaccine serotypes such as 19A and 15A 357	  
have been reported following the introduction of the PCV7 and PCV13 outside SSA.41,42 The 358	  
increase in the proportion S. pneumoniae that are penicillin resistant at a time when S. 359	  
pneumoniae BSI is in decline raises the possibility that there has been a change in serotype 360	  
distribution following vaccine introduction as has been the case in the other settings.41,42 361	  
 362	  
In this study, we also describe the emergence of MRSA, yet it currently remains an infrequent 363	  
cause of BSI in Blantyre. Prevalence of MRSA amongst the S. aureus isolates is similar to 364	  
proportions from countries such as Mozambique and Zimbabwe, but much lower to those 365	  
reported in South Africa.43-45  This may be a reflection of the fact that our cultures were taken 366	  
from community admissions to medical wards; we have yet to study nosocomial infection in 367	  
depth in our setting. It might also reflect that unlike in South Africa, medical devices placing 368	  
patients at risk of MRSA BSI such as central venous catheters are uncommonly used in low 369	  
income countries such as Malawi. The sustained presence of MRSA as a low-level cause of BSI 370	  
in Blantyre is therefore of considerable concern as its relative importance as a BSI pathogen may 371	  
greatly change if surveillance expands to cover surgical patients or nosocomial infections or if 372	  
medical practice changes, for example a renal dialysis unit is under development at QECH.  373	  
 374	  
Limitations 375	  
This study describes a comprehensive and extensive dataset from a sustained period of 376	  
bacteraemia surveillance, however it has a number of limitations. The median length of stay for 377	  
adult internal medicine inpatients is five days and is shorter for children.46 Typically patients at 378	  
QECH undergo BC on admission but it was uncommon for patients to have follow-up BC and it 379	  
is therefore unlikely that our surveillance has captured much nosocomial infection. It is possible 380	  
that community acquired sepsis was missed if persons died at home or were not referred to 381	  
hospital, hence we consider rates reported to be minimum estimates. 382	  
 383	  
Antimicrobial susceptibility profile was described for 96·7% of the isolates and reflect BSAC 384	  
guidelines at time of testing. ESBL screening was not introduced until 2003, and as such ESBL-385	  
producing pathogens may have been circulating, but undetected before then. ESBL screening by 386	  
cefpodoxime disc testing was not introduced until 2007, consequently some isolates may have 387	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been falsely classified as ESBL producing prior to 2007. In the case of S. aureus, cefoxitin 388	  
screening for MRSA replaced methicillin in 2010, although the small increase in sensitivity 389	  
gained will have made minimal difference to the reported findings. 390	  
 391	  
CONCLUSIONS 392	  
The overall declines in bacterial BSI have been accompanied by a rise in antimicrobial resistance 393	  
in all bacterial BSI pathogens at QECH, especially in Gram-negative organisms, and the 394	  
emergence of methicillin resistance in S. aureus. Ceftriaxone and ciprofloxacin have been 395	  
essential for the management of bacterial BSI in a context where human immunosuppression and 396	  
bacterial multidrug resistance are highly prevalent. The emergence of ESBL, fluoroquinolone 397	  
and gentamicin resistance and MRSA highlight the growing challenge of BSIs that are 398	  
effectively impossible to treat in this resource-limited setting. 399	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FIGURE LEGENDS  572	  
Figure 1: Trends in BSI 1998-2016. 1A: Annual frequency of blood culture sampling, and 573	  
pathogen and contaminant isolation, plus estimated minimum incidence rates of BSI. 1B-D 574	  
Estimated minimum incidence of pathogens isolated at high frequency (≥300/year -1B) and 575	  
intermediate frequency (50-299/year - 1C & 1D). Pathogens isolated at low frequency (<50 year) 576	  
are depicted in 1E. 577	  
Figure 2: Estimated minimum incidence rates of BSI stratified by age for (2A) S. Typhimurium 578	  
(2B) S. Enteritidis (2C) S. Typhi, (2D) E. coli, (2E) Klebsiella spp., (2F) other 579	  
Enterobacteriaceae, (2G) S. pneumoniae, (2H) S. aureus  (2I) Yeast. 580	  
Figure 3: Trends in proportions of isolates resistant to Malawian first line antimicrobials for 581	  
(3A) E. coli, (3B) Klebsiella spp., and (3C) other Enterobacteriaceae, (3D) S. pneumoniae, (3E), 582	  
S. aureus  and (3F) other Streptococcus/Enterococcus spp.  First line antimicrobials include 583	  
chloramphenicol and cotrimoxazole, plus ampicillin for gram negative pathogens and penicillin 584	  
for gram positive pathogens. 585	  
Figure 4: Trends in resistance to second-line antimicrobial agents (ciprofloxacin, ceftriaxone 586	  
and gentamicin) in (A) E. coli, (B) Klebsiella spp. and (C) other Enterobacteriaceae and (D) 587	  
trend in number of isolates resistant to all six commonly used antimicrobial agents in Malawi 588	  
(*ampicillin, chloramphenicol, cotrimoxazole, ceftriaxone, ciprofloxacin and gentamicin).	  589	  
	  590	  
TABLES	  591	  
 592	  
 593	  
 594	  
 595	   	  596	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Table 1: Prevalence of significant pathogens in four time intervals: 1998-2001, 2002-2005 , 597	  
2006-2009, 2010-2013 and 2014-2016. 598	  
Organism No. of isolates (%) 
  1998-2001 2002-2005 2006-2009 2010-2013 2014-2016 Total 
Acinetobacter spp.  200 (3·0) 126 (1·0) 115 (2·0) 64 (1·5) 40 (1·0) 545 (1·9) 
Anaerobes 7 (0·0) 8 (0·0) 7 (0·0) 6 (0·1) 2 (0·1) 30 (0·1) 
Citrobacter spp. 69 (1·0) 75 (0·8) 20 (0·4) 9(0·2) 12 (0·3) 185 (0·6) 
E. coli 592 (9·0) 661 (7·0) 552 (10·0) 398 (9·3) 357(9·3) 2560 (8·8) 
E. faecalis 48 (0·7) 57 (0·6) 61 (1·1) 27 (0·6) 27(0·7) 220 (0·8) 
Edwardsiella spp. - 2 (0·0) - - - 2 (0·0) 
Enterobacter 93 (1·3) 173 (2·0) 88 (1·6) 74 (1·7) 89(2·3) 517 (1·8) 
Enterococcus spp.  14 (0·2) 2 (0·0) 2 (0·0) 64 (1·5) 69 (1·8) 151 (0·5) 
Escherichia spp. - 3 (0·0) 3 (0·1) - - 6 (0·0) 
Flavobacteria spp.  2 (0·0) 2 (0·0) 2 (0·0) - - 6 (0·0) 
H. influenza type b 112 (1·6) 92 (1·0) 26 (0·5) 30  (0·7) 15 (0·4) 275 (0·9) 
Haemophilus spp. 41 (0·6) 53 (0·6) 36 (0·7) 21 (0·5) 8 (0·2) 434 (0·5) 
Hafnia spp. 3 (0·0) 2 (0·0) 1 (0·0) -  6 (0·0) 
Klebsiella spp. 449 (7·0) 248 (3·0) 211 (4·0) 190 (4·4) 183 (4·8) 1281 (4·4) 
Kluyvera spp. 2 (0·0) 1 (0·0) 2 (0·0) 2 (0·0) - 7 (0·0) 
M. morganii - 3 (0·0) 4 (0·1) 11 (0·3) 1 (0·0) 19 (0·1) 
Mycobacterium 60 (1·0) - - -  60 (0·2) 
Neisseria 78 (1·0) 27 (0·0) 42 (1·0) 34 (0·8) 39(1·0) 220 (0·8) 
Other Gram Negative cocci 15 (0·0) 11 (0·0) 11 (0·2) 1 (0·0) - 38 (0·1) 
Other Gram-negative rods 18 (0·0) 45 (1·0) 41 (1·0) 55 (1·3) 7 (0·2) 166 (0·6) 
NTS 2,685 (38·9) 4,432 (50·1) 2,141 (40·2) 782 (18·3) 433 (11·3) 10473 (35·9) 
Streptococcus spp. 115 (1·7) 113 (1·3) 55 (1·0) 46 (1·1) 57 (1·5) 386 (1·3) 
Pantoea spp. - - - 11(0·3) 9 (0·2) 20 (0·1) 
Proteus spp. 47 (0·7) 9 (0·1) 12 (0·2) 7 (0·2) 18 (0·5) 93 (0·3) 
Pseudomonas 98 (1·0) 102 (1·0) 41 (1·0) 126 (2·9) 75 (2·0) 442 (1·5) 
Raoultella spp. - - - 3 (0·1) 8 (0·2) 11 (0·0) 
S. agalactiae 173 (2·5) 155 (1·8) 40 (0·8) 70 (1·3) 17 (0·4) 455 (1·6) 
S. aureus 505 (7·0) 480 (5·0) 258 (5·0) 344 (8·0) 338 (8·8) 1925 (6·6) 
S. pneumoniae 1,139 (17·0) 1,476 (17·0) 1,072 (20·0) 448 (10·5) 123 (3·2) 4258 (14·6) 
Group A Streptococcus 117 (1·7) 102 (1·2) 69 (1·3) 59(1·4) 50 (1·3) 397 (1·4) 
S. Typhi 67 (1·0) 49 (1·0) 70 (1·0) 1168 (27·3) 1643 (43·0) 2997(10·3) 
Serratia spp. 92 (1·3) 66 (0·7) 15 (0·3) 21 (0·5) 17 (0·4) 211(0·7) 
Shigella spp. 1 (0·0) 9 (0·1) 18 (0·3) 6 (0·1) 6 (0·2) 40 (0·1) 
Vibrio spp. 5 (0·0) 2 (0·0) 2 (0·0) 3 (0·1) - 12 (0·0) 
Yersinia  2 (0·0) 2 (0·0) 1 (0·0) 2 (0·0) - 7 (0·0) 
Candida spp. 4 (0·0) 6 (0·1) 4 (0·1) 13 (0·3) 13 (0·3) 40 (0·1) 
Cryptococcus spp. 50 (1·0) 249 (2·8) 300 (5·6) 195 (4·6) 169 (4·4) 963 (3·3) 
Total 6,903 8,843 5,322 4290 3825 29183 
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Table	  2:	  Trends	   in	   frequency	  of	  MDR	  bacterial	  BSI	   pathogens	   in	  Blantyre	  between	  599	  
1998	  and	  2016.	  Isolates	  are	  considered	  MDR	  when	  found	  to	  be	  resistant	  to	  at	   least	  600	  
three	  antimicrobial	  classes.	   601	  
Year E. coli Klebsiella 
spp. 
Enterobacter
iaceae 
S. pneumoniae Enterococcus 
spp. 
Streptococcus 
spp. 
1998 111/185(60) 66/146 (45·2) 22/30 (73·3) 85/335 (25·4) 18/26 (69·2) 18/90 (20·0) 
1999 118/150(78·7) 31/113 (27·4) 12/26 (46·2) 98/313 (31·3) 8/13 (61·5) 15/93 (16·1) 
2000 83/116 (71·6) 38/101 (37·6) 60/90 (66·7) 80/238 (33·6) 3/8 (37·5) 21/143 (14·7) 
2001 96/124 (77·4) 17/73 (23·3) 87/131 (66·4) 41/154 (26·6) 10/15 (66·7) 13/70 (18·6) 
2002 113/147 (76·9) 20/81 (24·7) 64/80 (80·0) 75/231 (32·5) 2/7 (28·6) 8/72 (11·1) 
2003 110/152 (72·4) 24/52 (46·2) 67/108 (62·0) 116/316 (36·7) 2/3 (66·7) 13/74 (17·6) 
2004 92/133 (69·2) 21/46 (45·7) 39/62 (62·9) 83/265 (31·3) 5/7 (71·4) 22/79 (27·8) 
2005 121/181 (66·9) 22/46 (47·8) 24/55 (43·6) 158/494 (32·0) 32/41 (78·0) 28/114 (24·6) 
2006 84/186 (45·2) 18/52 (34·6) 45/76 (59·2) 110/413 (26·6) 6/13 (46·2) 15/70 (21·4) 
2007 81/136 (59·6) 27/57 (47·4) 15/31 (48·4) 105/320 (32·8) 9/14 (64·3) 10/46 (21·7) 
2008 81/116 (69·8) 36/55 (65·5) 10/27 (37·0) 54/160 (33·8) 12/14 (85·7) 6/29 (20·7) 
2009 60/106 (56·6) 29/40 (72·5) 12/22 (54·5) 47/151 (31·1) 12/17 (70·6) 4/16 (25·0) 
2010 64/96 (66·7) 34/45 (75·6) 25/34 (73·5) 34/119 (28·6) 10/13 (76·9) 13/28 (46·4) 
2011 76/109 (69·7) 35/48 (72·9) 10/15 (66·7) 71/177 (40·1) 6/7 (85·7) 28/71 (39·4) 
2012 42/86 (48·8) 32/38 (84·2) 17/27 (63·0) 30/106 (28·3) 15/16 (93·8) 7/41 (17·1) 
2013 74/100 (74·0) 33/55 (60·0) 42/61 (68·9) 12/41 (29·3) 15/17 (88·2) 25/58 (43·1) 
2014 63/105 (60·0) 41/51 (80·4) 40/57 (70·2) 12/31 (38·7) 15/18 (83·3) 16/53 (30·2) 
2015 65/118 ( 55·1) 39/48 (81·3) 10/33 (30·3) 25/50 (50·0) 29/34 (85·3) 19/46 (40·3)  
2016 92/133 (69·2) 77/84 (91·7) 51/65 (78·5) 9/42 (21·4) 37/48 (77·1) 8/31 (25·8) 
Overall 1626/2479 
(65·6) 
640/1231 
(52·0) 
652/932 
(63·3) 
1245/3956 
(31·5) 
246/331 
(74·3) 
289/1224 
(23·6) 
p-value <0·0001* <0·0001** 0·747 0·148 <0.0001** <0·0001** 
*= decreasing trend; **=increasing trend. 602	  
 603	  
 604	  
 605	  
 606	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RESEARCH IN CONTEXT PANEL 607	  
Evidence before this study 608	  
Long-term surveillance data describing bloodstream infection (BSI) and antimicrobial resistance 609	  
(AMR) in sub-Saharan Africa (SSA) are scarce. A systematic review and meta-analysis of 610	  
community-acquired BSI in Africa by Reddy et al identified only 22 studies over a period of 611	  
more than 20 years (up to June 2009) and the majority (13) focused on children. Only one study 612	  
from Egypt and none from SSA reported long-term (1999-2003) surveillance data for both 613	  
children and adults, and only 13 studies reported antimicrobial susceptibility data. 614	  
A review of more recent literature available on PubMed (search strategy: (“Africa”) AND 615	  
(“community acquired”) AND (“bacteraemia” OR “sepsis”)) for the period July 2009-June 2016 616	  
revealed two large bacteraemia datasets; one from South Africa (Dramowski et al) containing 617	  
17,001 blood culture results from a 6 year period and the other from Mozambique (Mandomando 618	  
et al) containing a further 19,896 blood culture results from a 5 year period. These studies 619	  
reported trends in community acquired BSI and AMR in all pathogens, but only for paediatric 620	  
patients. We found no studies detailing longitudinal passive BSI surveillance from both adults 621	  
and children.  622	  
Added value of this study 623	  
Like many sub-Saharan African countries, Malawi is under considerable pressure from poverty, 624	  
undernutrition, urbanization and malaria. In addition, in the context of a high HIV 625	  
seroprevalence, ART rollout has been highly successful. Blantyre is a major African city, 626	  
grappling with the same issues of rapid expansion in population size with insufficient access to 627	  
water and sanitation as elsewhere on the continent. Our data are therefore representative of urban 628	  
Africa.  629	  
 630	  
We present the largest bacteraemia and AMR surveillance dataset yet collected from SSA and 631	  
describe trends in BSI in both adults and children presenting to a major urban teaching hospital 632	  
in Malawi over a 19-year period. Our study reveals a marked decline in the incidence of BSI 633	  
caused by all pathogens except S. Typhi. This has occurred concurrently with a number of major 634	  
public health interventions, including the extensive roll out of both antiretroviral therapy and 635	  
malaria control interventions, improvements in food security and the community management of 636	  
malnutrition, and the introduction of Haemophilus influenza type b and pneumococcal conjugate 637	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vaccines. This good news is tempered by the emergence and rapid expansion of drug resistant 638	  
pathogens, including cephalosporin and fluoroquinolone resistant Enterobacteriaceae, penicillin 639	  
resistant S. pneumoniae and methicillin resistant S. aureus. These surveillance data are critical to 640	  
improving the understanding of the burden of severe, drug resistant bacterial infection in SSA. 641	  
Implications 642	  
Although there has been a marked fall in community-acquired bacterial BSI in Malawi, an 643	  
increasing number of pathogens are becoming effectively untreatable due to their resistance to 644	  
locally available antimicrobial agents.  645	  
 646	  
SUPPLEMENTARY APPENDIX 647	  
Supplementary Table 1: Distribution of isolates from children with BSI by pathogen and year 648	  
of isolation  649	  
Supplementary Table 2: Distribution of isolates from adults with BSI by pathogen and year of 650	  
isolation  651	  
Supplementary Table 3: Distribution of isolates by pathogen resistance profile and year of 652	  
isolation.  653	  
Supplementary Figure 1: Distribution of contaminants as proportions of all blood cultures (BC) 654	  
 655	  
Supplementary Figure 2: Age distributions of patients presenting to QECH between 1998 and 656	  
2016 with confirmed BSI caused by (A) S. Typhimurium, (B) S. Enteritidis, (C) S. Typhi, (D) E. 657	  
coli, (E) Klebsiella spp., (F) other Enterobacteriaceae, (G) S. pneumoniae, (H) S. aureus and (I) 658	  
yeast. 659	  
Supplementary Figure 3: Trends in resistance to first-line agents amongst in (A) all bacterial 660	  
pathogens and (B) all Salmonellae isolates. As with Figure 3, first line antimicrobials include 661	  
chloramphenicol and cotrimoxazole, plus ampicillin for gram negative pathogens and penicillin 662	  
for gram positive pathogens. 663	  
 664	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Supplementary Figure 4: Trends in annual incidence (per 100,000) of Enterobacteriaceae 665	  
resistant to ceftriaxone (CRO-R) or ciprofloxacin (CIP-R). A. Annual incidence of CRO-R E. 666	  
coli; B. Annual incidence of CIP-R E. coli; C. Annual incidence of CRO-R Klebsiella spp;  667	  
Annual incidence of CIP-R Klebsiella spp. E. Annual incidence of Other CRO-R 668	  
Enterobacteriaceae; F. Annual incidence of other CIP-R Enterobacteriaceae. In For each panel, 669	  
points represent observed annual incidence rates while the black line graph represent annual 670	  
incidence rates predicted by a linear regression model with the general form , 671	  
where  is the incidence rate,  is the year of isolation and  and  are constant coefficients. 672	  
Supplementary Figure 5: Trends in proportions of Acinetobacter spp. isolates resistant to 673	  
ceftriaxone, ciprofloxacin and gentamicin during 1998-2016. 674	  
 675	  
PANELS 676	  
Panel 1: Research in context  677	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Figure 1: Distributions of blood culture samples. Year by year distribution of all blood culture samples  by category is depicted in Figure 1A while 
distributions of blood cultures which grew into significant pathogens are shown in Figures 1B-E, (Pathogens were classified into four groups of high 
frequency isolation, (≥ 300 isolates in any year – Figure 1B), Gram-negative medium frequency isolation pathogens and Gram-positive medium isolation 
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Figure 2: Estimated minimum incidence rates of BSI stratified by age for (A) S. Typhimurium, 
(B) S. Enteritidis (C) S. Typhi, (D) E. coli, (E) Klebsiella spp., (F) other Enterobacteriaceae, 
(G) S. pneumoniae, (H) S. aureus  (I) Yeast.
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Figure 3: Trends in proportions of RFL isolates (resistant to chloramphenicol, cotrimoxazole and ampicillin) for (A) E. coli (B) Klebsiella spp.   and 
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Supplementary Figure 1: Distribution of contaminants as proportions of all BCs by year of 708	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Supplementary Figure 2: Age distributions of patients presenting to QECH between 1998 and 711	  
2014 with confirmed BSI caused by (A) S. Typhimurium, (B) S. Enteritidis, (C) S. Typhi, (D) E. 712	  
coli, (E) Klebsiella spp., (F) other Enterobacteriaceae, (G) S. pneumoniae, (H) S. aureus and (I) 713	  
yeast. 714	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Supplementary Figure 3: Trends in resistance to first-line agents amongst in (A) all bacterial 718	  
pathogens and (B) all Salmonellae isolates. As with Figure 3, first line antimicrobials include 719	  
chloramphenicol and cotrimoxazole, plus ampicillin for Gram-negative pathogens and penicillin 720	  
for gram positive pathogens. 721	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Supple722	  
mentary Figure 4: Trends in annual incidence (per 100,000) of Enterobacteriaceae resistant to 723	  
ceftriaxone (CRO-R) or ciprofloxacin (CIP-R). A. Annual incidence of CRO-R E. coli; B. 724	  
Annual incidence of CIP-R E. coli; C. Annual incidence of CRO-R Klebsiella spp;  Annual 725	  
incidence of CIP-R Klebsiella spp.; E. Annual incidence of Other CRO-R Enterobacteriaceae; F. 726	  
Annual incidence of other CIP-R Enterobacteriaceae. In For each panel, points represent 727	  
observed annual incidence rates while the black line graph represent annual incidence rates 728	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predicted by a linear regression model with the general form , where  is the 729	  
incidence rate,  is the year isolation and  and  are constant coefficients.  730	   	  731	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Supplementary Figure 5: Trends in proportions of Acinetobacter spp. isolates resistant to 734	  
ceftriaxone, ciprofloxacin and gentamicin during 1998-2016. 735	   	  736	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